Beth Fischer

1.1k total citations
28 papers, 829 citations indexed

About

Beth Fischer is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Beth Fischer has authored 28 papers receiving a total of 829 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Beth Fischer's work include Chronic Lymphocytic Leukemia Research (23 papers), Lymphoma Diagnosis and Treatment (14 papers) and Advanced Breast Cancer Therapies (12 papers). Beth Fischer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (23 papers), Lymphoma Diagnosis and Treatment (14 papers) and Advanced Breast Cancer Therapies (12 papers). Beth Fischer collaborates with scholars based in United States, Austria and Germany. Beth Fischer's co-authors include Michael R. Grever, John C. Byrd, Thomas S. Lin, Mollie E. Moran, Kristie A. Blum, Amy J. Johnson, Mitch A. Phelps, Nyla A. Heerema, Larry J. Schaaf and James T. Dalton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Beth Fischer

27 papers receiving 811 citations

Peers

Beth Fischer
Kedar Inamdar United States
Laurent Vallat France
Simon He Australia
Ricardo Parrondo United States
Rosalind H. Gunby Italy
Elisabeth Walsby United Kingdom
Dan Costin United States
Jennifer E. Amengual United States
Cory Mavis United States
Kedar Inamdar United States
Beth Fischer
Citations per year, relative to Beth Fischer Beth Fischer (= 1×) peers Kedar Inamdar

Countries citing papers authored by Beth Fischer

Since Specialization
Citations

This map shows the geographic impact of Beth Fischer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Fischer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Fischer more than expected).

Fields of papers citing papers by Beth Fischer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beth Fischer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Fischer. The network helps show where Beth Fischer may publish in the future.

Co-authorship network of co-authors of Beth Fischer

This figure shows the co-authorship network connecting the top 25 collaborators of Beth Fischer. A scholar is included among the top collaborators of Beth Fischer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beth Fischer. Beth Fischer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Awan, Farrukh T., Amy J. Johnson, Rosa Lapalombella, et al.. (2010). Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leukemia & lymphoma. 51(1). 27–38. 23 indexed citations
2.
Lin, Thomas S., Amy S. Ruppert, Amy J. Johnson, et al.. (2009). Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease. Journal of Clinical Oncology. 27(35). 6012–6018. 178 indexed citations
3.
Fischer, Beth, et al.. (2009). Flavopiridol (alvocidib) in chronic lymphocytic leukemia. 2(5). 2 indexed citations
4.
Maddocks, Kami J., Rosa Lapalombella, Kristie A. Blum, et al.. (2009). Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.. Blood. 114(22). 3446–3446. 4 indexed citations
5.
Phelps, Mitch A., Thomas S. Lin, Amy J. Johnson, et al.. (2008). Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 113(12). 2637–2645. 128 indexed citations
6.
Lin, Thomas S., Nyla A. Heerema, Gerard Lozanski, et al.. (2008). Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities. Blood. 112(11). 46–46. 12 indexed citations
7.
8.
Blum, Kristie A., Donn C. Young, Margaret S. Lucas, et al.. (2007). Computed Tomography Scans Do Not Improve the Predictive Power of 1996 National Cancer Institute–Sponsored Working Group Chronic Lymphocytic Leukemia Response Criteria. Journal of Clinical Oncology. 25(35). 5624–5629. 13 indexed citations
9.
Heerema, Nyla A., John C. Byrd, Leslie A. Andritsos, et al.. (2007). Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).. Blood. 110(11). 3107–3107. 3 indexed citations
10.
Christian, Beth, Beth Fischer, Kristie A. Blum, et al.. (2007). Flavopiridol in Chronic Lymphocytic Leukemia. 1(5). 292–297. 4 indexed citations
11.
Lin, Thomas S., Mitch A. Phelps, James T. Dalton, et al.. (2006). Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.. Blood. 108(11). 2845–2845. 4 indexed citations
12.
13.
Byrd, John C., T. S. Lin, James T. Dalton, et al.. (2006). Pharmacologically derived schedule of flavopiridol has significant efficacy in refractory, genetically high risk chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 24(18_suppl). 6516–6516. 7 indexed citations
14.
Otterson, Gregory A., James P. Lavelle, Miguel A. Villalona‐Calero, et al.. (2005). A Phase I Clinical and Pharmacokinetic Study of Fenretinide Combined with Paclitaxel and Cisplatin for Refractory Solid Tumors. Investigational New Drugs. 23(6). 555–562. 7 indexed citations
15.
16.
Lin, Thomas S., Beth Fischer, Mollie E. Moran, et al.. (2005). Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.. Blood. 106(11). 944–944. 4 indexed citations
17.
Lin, Thomas S., James T. Dalton, Di Wu, et al.. (2004). Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-hr continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology. 22(14_suppl). 6564–6564. 5 indexed citations
18.
19.
20.
Villalona‐Calero, Miguel A., M. Guillaume Wientjes, Gregory A. Otterson, et al.. (2003). Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.. PubMed. 9(9). 3303–11. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kedar Inamdar Breakdown of academic impact, for papers by Laurent Vallat Breakdown of academic impact, for papers by Simon He Breakdown of academic impact, for papers by Ricardo Parrondo Breakdown of academic impact, for papers by Rosalind H. Gunby Breakdown of academic impact, for papers by Elisabeth Walsby Breakdown of academic impact, for papers by Dan Costin Breakdown of academic impact, for papers by Jennifer E. Amengual Breakdown of academic impact, for papers by Cory Mavis
Rankless by CCL
2026